Trial Profile
RADVAX™: A Pilot Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- 22 Apr 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 22 Apr 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2017.
- 02 Jan 2018 Status changed from not yet recruiting to recruiting.